A new Lipitor lawsuit alleging the cholesterol medication’s potential to cause Type 2 diabetes has been filed in Kentucky federal court by a woman who says its manufacturer failed to warn about this risk.
The plaintiff in this case, who allegedly developed Type 2 diabetes after taking Lipitor for four years, claims that Pfizer, Inc. had knowledge that its product could lead to elevated blood glucose levels, but continued to market it as safe and effective anyway. In fact, it was not until February 2012 that the drug’s labeling began to include a warning for Lipitor diabetes after the company was mandated to do so by the U.S. Food and Drug Administration (FDA). This lawsuit further alleges that the current labeling is insufficient, however, and individuals may still not be aware of the serious Type 2 diabetes risks posed by Lipitor.
This claim, which was filed in the U.S. District Court, Western District of Kentucky, is the latest to be filed over the medication, which was approved by the FDA for use in lowering LDL (bad) cholesterol and triglycerides in individuals who may be at an elevated risk for strokes, heart attacks, and other cardiovascular problems. However, a growing number of claims are alleging skeletal and muscle side effects, as well as kidney and liver damage in addition to new-onset diabetes. Plaintiffs in Lipitor lawsuits have requested that similar actions against Pfizer be coordinated in a single federal proceeding to conserve the resources of the court. According to a petition filed in October 2013 with the U.S. Judicial Panel on Multidistrict Litigation (JPML), at least 100 claims were pending in courts throughout the U.S. Individuals who have brought these claims have proposed that the Lipitor lawsuits be consolidated in the U.S. District Court, District of South Carolina. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502 (JPML))
This was the second request for a multidistrict litigation to be filed with the Panel, following one in April that noted less than a dozen cases over Lipitor. The JPML has not scheduled a hearing on whether to approve the most recent petition.
The possibility of creating a federal Lipitor litigation has been met with opposition from Pfizer, however. According to a Response filed with the Panel on November 1st, the company argued that consolidation would delay the litigation’s progress.
If you were diagnosed with diabetes after taking Lipitor, you may have a case against the cholesterol drug’s manufacturer. Call our Firm now at .